Kamei K, Tsuchida S, Nishikibe M
Central Research Laboratories, Banyu Pharmaceutical Co., Ltd., Tokyo, Japan.
Nihon Yakurigaku Zasshi. 1989 Jun;93(6):341-7. doi: 10.1254/fpj.93.341.
Effects of NB-818, a new Ca2+ entry blocker, on a transient cerebral ischemic model in Mongolian gerbils were examined. Following bilateral common carotid arteries occlusion of 20 min duration, all the control animals died within 24 hr after reperfusion. The administration of NB-818 at 0.1 mg/kg, i.p., 30 min after reperfusion significantly reduced the mortality rate to 65.0% (P less than 0.01); and 0.01 mg/kg, i.p., had a tendency to reduce the mortality rate. In the nimodipine-treated groups, a similar effects in the ischemic model. Furthermore, the administration of NB-818 at 0.1 mg/kg, i.p., 15 min before occlusion also had a tendency to reduce the mortality rate. On the incidences of seizures induced by transient cerebral ischemia, there were no significant differences between each of the drug-treated groups and the control group. In NB-818 and nimodipine-treated groups, the morbidity scores NB-818 and nimodipine in this severe cerebral ischemic model have advantages over those of nicardipine and flunarizine. Thus, these results suggest that NB-818 may be useful in the treatment of ischemic cerebral damage.
研究了新型钙离子通道阻滞剂NB - 818对蒙古沙土鼠短暂性脑缺血模型的影响。在双侧颈总动脉闭塞20分钟后，所有对照动物在再灌注后24小时内死亡。再灌注后30分钟腹腔注射0.1mg/kg的NB - 818可使死亡率显著降低至65.0%（P<0.01）；腹腔注射0.01mg/kg有降低死亡率的趋势。在尼莫地平治疗组中，缺血模型有类似效果。此外，在闭塞前15分钟腹腔注射0.1mg/kg的NB - 818也有降低死亡率的趋势。关于短暂性脑缺血诱发癫痫的发生率，各药物治疗组与对照组之间无显著差异。在该严重脑缺血模型中，NB - 818和尼莫地平治疗组的发病率评分优于尼卡地平组和氟桂利嗪组。因此，这些结果表明NB - 818可能对缺血性脑损伤的治疗有用。
